Download PDF
Thromb Haemost 2017; 117(02): 415-421
DOI: 10.1160/TH16-07-0566
Trial Protocol Design Paper
Schattauer GmbH

RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate

Walter Ageno
1   University of Insubria, Varese, Italy
,
Ivan B. Casella
2   University of Sao Paulo, Sao Paulo, Brazil
,
Chee Kok Han
3   University of Malaya, Kuala Lumpur, Malaysia
,
Gary E. Raskob
4   University of Oklahoma Health Sciences Center, Oklahoma, USA
,
Sebastian Schellong
5   Stadtisches Klinikum Dresden, Dresden, Germany
,
Sam Schulman
6   Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada
,
Daniel E. Singer
7   Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
,
Karen Kimura
8   Boehringer Ingelheim Canada, Burlington, Ontario, Canada
,
Wenbo Tang
9   Boehringer Ingelheim, Germany
,
Marc Desch
9   Boehringer Ingelheim, Germany
,
Samuel Z. Goldhaber
10   Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
› Author Affiliations
Further Information

Publication History

Received:23 July 2016

Accepted:14 October 2016

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

Summary

The therapeutic management of venous thromboembolism (VTE) is rapidly evolving. Following the positive results of pivotal large-scale randomised trials, the non-vitamin K antagonist oral anticoagulants (NOACs) represent an important alternative to standard anticoagulation. In phase III studies, dabigatran was as effective as, and significantly safer than warfarin. Additional information on real-world data of dabigatran is now warranted. RE-COVERY DVT/PE is a multi-centre, international, observational (i. e. non-interventional) study enrolling patients with acute DVT and/or PE within 30 days after objective diagnosis. The study is designed with two phases. Phase 1 has a cross-sectional design, enrolling approximately 6000 patients independently of treatment choice, with the aim of providing a contemporary picture of the management of VTE worldwide. Phase 2 has a prospective cohort design, with follow-up of one year, enrolling 8000 patients treated with dabigatran or vitamin K antagonists (VKAs) with the aim of comparing their safety, defined by the occurrence of major bleeding, and effectiveness, defined by the occurrence of symptomatic recurrent VTE. RE-COVERY DVT/PE will complement both the results of other observational studies in this field and the results of phase III studies with dabigatran, in particular by assessing its clinical benefit in various patient subgroups treated in routine clinical practice.

Keywords

Deep-vein thrombosis - pulmonary embolism - dabigatran - anticoagulation
 

  • References

  • 1 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12: 1580-1590.
    CrossrefPubMedGoogle Scholar
  • 2 Dentali F, Ageno W, Pomero F. et al. Time trends and case fatality rate of pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 2016; 115: 399-405.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Konstantinides SV, Warntges S. Acute phase treatment of venous thromboembolism: advanced therapy. Thromb Haemost 2015; 113: 1202-1209.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. Haematologica 2007; 92: 199-205.
    CrossrefPubMedGoogle Scholar
  • 5 Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145: 286-295.
    CrossrefPubMedGoogle Scholar
  • 6 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
    CrossrefPubMedGoogle Scholar
  • 7 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-e494S.
    CrossrefPubMedGoogle Scholar
  • 8 Ageno W, Gallus AS, Wittkowsky A. et al. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e44S-88S.
    CrossrefPubMedGoogle Scholar
  • 9 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
    CrossrefPubMedGoogle Scholar
  • 10 Lecumberri R, Alfonso A, Jimenez D. et al. Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013; 110: 834-843.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113: 231-246.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 van Es N, Coppens M, Schulman S. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
    CrossrefPubMedGoogle Scholar
  • 13 Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs 2013; 73: 1171-1182.
    CrossrefPubMedGoogle Scholar
  • 14 Schulman S, Kearon C, Kakkar AK. et al. RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
    CrossrefPubMedGoogle Scholar
  • 15 Konstantinides SV, Torbicki A, Agnelli G. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-3069k.
    CrossrefPubMedGoogle Scholar
  • 16 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352.
    CrossrefPubMedGoogle Scholar
  • 17 Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123: 1436-1450.
    CrossrefPubMedGoogle Scholar
  • 18 Eisert WG, Hauel N, Stangier J. et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-1889.
    CrossrefPubMedGoogle Scholar
  • 19 Stangier J, Rathgen K, Stähle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
    CrossrefPubMedGoogle Scholar
  • 20 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S.
    CrossrefPubMedGoogle Scholar
  • 21 Schulman S, Kearon C, Kakkar AK. et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
    CrossrefPubMedGoogle Scholar
  • 22 Schulman S, Kakkar AK, Goldhaber SZ. et al. RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
    CrossrefPubMedGoogle Scholar
  • 23 Schulman S, Eriksson H, Goldhaber S. et al. Major bleeding events with dabigatran versus warfarin in patients with acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Scientific and Standardisation Committee Meeting of the ISTH - 60th Annual Meeting 2014; 12: 1-106 (Abstract).
    PubMedGoogle Scholar
  • 24 Graham DJ, Reichman ME, Wernecke M. et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
    CrossrefPubMedGoogle Scholar
  • 25 Huisman MV, Lip GY, Diener HC. et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014; 167: 329-334.
    CrossrefPubMedGoogle Scholar
  • 26 Ageno W, Mantovani LG, Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 03: e12- e21.
    PubMedGoogle Scholar
  • 27 Schulman S, Eriksson H, Goldhaber S. et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood 2013; 122: 2375 (Abstract).
    PubMedGoogle Scholar
  • 28 Schulman S, Eriksson H, Kakkar A. et al. Influence of age and renal function on efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER™ and RE-COVER™ II. Blood 2014; 124: 594 (Abstract).
    PubMedGoogle Scholar
  • 29 Schulman S, Eriksson H, Goldhaber S. et al. Influence of renal function on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II. Blood 2013; 122: 212 (Abstract).
    PubMedGoogle Scholar
  • 30 Schulman S, Eriksson H, Goldhaber S. et al. Influence of Active Cancer on the Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis From RE-COVER and RE-COVER II. Blood 2013; 122: 582 (Abstract).
    PubMedGoogle Scholar